Clinical trials: LAM
HIV Infections, Pregnancy
Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies
The purpose of this study is to see if it is safe and effective to give ritonavir (RTV) plus lamivudine (3TC) plus zidovudine (ZDV) to HIV-infected pregnant women during pregnancy and to their babies after birth.
- Trial name
- NCT00000888
- Testing
- Ritonavir, Lamivudine, Zidovudine
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection
This trial tests the safety and effectiveness of the early use of combinations of anti-HIV drugs in HIV-infected infants and young children in an effort to block virus growth and preserve normal immune functions.
- Trial name
- NCT00000872
- Testing
- Abacavir sulfate, Nelfinavir mesylate, Nevirapine
- Where
- 12 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
Lymphangioleiomyomatosis, a Study on Cathepsin K
This is a physiopathological case-control, non-interventional, monocentric study of adult patients with lymphangioleiomyomatosis.
- Trial name
- LAM-CAK (NCT05323370)
- Testing
- 24h urine, urine sample
- Where
- France
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Sporadic Lymphangioleiomyomatosis, TSC-associated Lymphangioleiomyomatosis
The Genotype and Phenotype of Lymphangioleiomyomatosis
This study aims to differentiate between sporadic Lymphangioleiomyomatosis and Tuberous Sclerosis Complex-associated Lymphangioleiomyomatosis.
- Trial name
- NCT06405997
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Chronic Hepatitis B
Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B
The purpose of the study is to investigate the safety and the antiviral activity of ascending multiple oral doses of LB80380 for 12 weeks in adults with lamivudine-refractory chronic hepatitis B infection.
- Trial name
- NCT00895596
- Testing
- LB80380
- Where
- 4 sites in China, South Korea
- Volunteers
- 65 people
- Sponsor
- LG Life Sciences
Chronic Hepatitis B
Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects
The purpose of this study is to evaluate the efficacy of Oxymatrine plus Lamivudine Combination Therapy and whether it could lower the incidence of Lamivudine long-term resistance compared to Lamivudine Monotherapy.
- Trial name
- NCT02202473
- Testing
- Lamivudine, Lamivudine+Oxymatrine Capsules
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Southeast University, China
HIV Infections
Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV
Cyclosporine A (CsA) is a common long-term treatment used to inhibit the immune response in transplant patients who receive donor organs. CsA may also help people with HIV.
- Trial name
- NCT00084149
- Testing
- Abacavir sulfate, Lamivudine, and Zidovudine, Lopinavir/Ritonavir
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Lymphangioleiomyomatosis
A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)
This trial is conducted locally. The aim of this trial is assess the efficacy and a favorable benefit-risk ratio for nintedanib in the treatment of LAM at the dose of 150 mg bid
- Trial name
- LAM (NCT03062943)
- Testing
- Nintedanib
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS Multimedica
HIV Infections
Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection
The purpose of this study is to compare changes in HIV levels and certain immune cells among patients at different stages of HIV infection.
- Trial name
- NCT00006443
- Testing
- Indinavir sulfate, Nelfinavir mesylate, Lamivudine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs
For a few years, there has been a keen interest of clinicians and patients for "lighter" antiretroviral strategies based on two- or even single drug regimens rather than the canonical triple therapy, both as initial and…
- Trial name
- IDOLTIB (NCT04034862)
- Testing
- Treatment simplification (dolutegravir lamivudine)
- Where
- Belgium
- Volunteers
- 36 people
- Sponsor
- University of Liege
HIV Infections
The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs
To evaluate the safety and tolerance of adefovir dipivoxil and indinavir administered orally in combination with zidovudine, lamivudine, or stavudine in HIV-infected patients with CD4 cell counts >= 100 cells/mm3 and an HIV-1 RNA…
- Trial name
- NCT00002379
- Testing
- Indinavir sulfate, Levocarnitine, Adefovir dipivoxil
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 100 people
- Sponsor
- Gilead Sciences
Hepatitis B Virus, Allograft
Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting
The purpose of this study is to evaluate the risk of hepatitis B reactivation in patients undergoing allografting.
- Conditions
- Hepatitis B Virus, Allograft, Hematological Malignancies
- Trial name
- NCT00876148
- Where
- Italy
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Drug-induced Hypotension
Study of Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in ART-Naive & First Switch Patients
Hypotension does not occur with Maraviroc at a dose of 600 mg/day
- Trial name
- NCT02626923
- Volunteers
- 51 people
- Sponsor
- Nicholaos C Bellos, MD
HIV-1-infection
Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites
This study will evaluate the intracellular pharmacokinetics and platelet effects of abacavir (ABC), lamivudine (3TC), tenofovir alafenamide (TAF), and emtricitabine (FTC) in persons living with HIV that are receiving these…
- Trial name
- NCT04301661
- Testing
- Blood collection, Abacavir/lamivudine, Tenofovir alafenamide/emtricitabine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Colorado, Denver
HIV-1 Infection
Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study
The purpose of this study is to evaluate the antiviral efficacy, safety and tolerability of dual therapy with 3TC and DTG as initial therapy among naïve HIV patients
- Trial name
- PADDLE (NCT02211482)
- Testing
- dolutegravir, lamivudine
- Where
- Argentina
- Volunteers
- 20 people
- Sponsor
- Fundación Huésped
Healthy
A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)
The goal of this study is to learn what happens to the medication islatravir (ISL), in a healthy person's body over time--called a pharmacokinetic (PK) study.
- Trial name
- NCT06811246
- Testing
- Islatravir (ISL), Lamivudine (3TC)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine
Dolutegravir (DTG) plus lamivudine (3TC) is a dual regimen combination recommended for both naïve and suppressed persons with HIV-1 infection1.
- Trial name
- VOLVER (NCT04880785)
- Testing
- Dolutegravir 50 MG / Lamivudine 300 MG Oral Tablet [Dovato]
- Where
- 17 sites in Spain
- Volunteers
- 167 people
- Sponsor
- Fundacion SEIMC-GESIDA
Hepatitis B, Chronic
Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA
This is a randomized, open-labelled, prospective 96-week study comparing the antiviral efficacy and safety of switching to entecavir 0.5mg QD from lamivudine versus maintaining lamivudine 100mg QD treatment in CHB patients…
- Trial name
- NCT00637663
- Testing
- Entecavir, Lamivudine
- Where
- 2 sites in South Korea
- Volunteers
- 72 people
- Sponsor
- Pusan National University Hospital
HIV Infections
Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir
The main objective of this clinical trial in randomizing HIV infected patients under good HIV control with tenofovir (TDF), emtricitabine (or lamivudine) plus lopinavir/ritonavir (LPV/r) into switching the regimen to raltegravir…
- Trial name
- SPARE (NCT01294761)
- Testing
- Raltegravir, Darunavir/r
- Where
- Japan
- Volunteers
- 59 people
- Sponsor
- National Center for Global Health and Medicine, Japan
Hepatitis C, HIV
Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
This study consists of 2 parts, Part A and Part B. Part A, the Phase 1 drug interaction/early viral kinetic study, will evaluate the effect of selected antiretroviral therapies on the safety, viral kinetics, and pharmacokinetics…
- Trial name
- NCT01565889
- Testing
- SOF, EFV/FTC/TDF, EFV
- Where
- Puerto Rico
- Volunteers
- 52 people
- Sponsor
- Gilead Sciences